SRDX

Surmodics, Inc. (SRDX) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Growth

Revenue growth is not provided in the fresh metrics, so the long-term top-line trajectory remains unconfirmed.

The company still appears to have a viable growth setup, but the current data does not show a clear acceleration signal.

Profitability

Gross margin remains strong at 71.5%, but operating margin is still negative at -16.0% and net margin at -18.3%.

Return metrics remain weak, with ROA at -6.2% and ROE at -9.5%, indicating the business is not yet generating durable earnings power.

Financial Health

Liquidity is solid with a current ratio of 3.9x and quick ratio of 3.1x.

Leverage remains manageable, with debt-to-equity at 0.29x and debt-to-assets at 19.2%, but cash generation is still thin.

Cash Flow

Free cash flow yield is only 0.25%, and free cash flow remains minimal relative to enterprise value.

Operating cash flow is positive, but conversion is weak given the high cash conversion cycle of 377 days.

Valuation

Valuation remains demanding at 10.8x EV/sales and 400.6x price-to-free-cash-flow.

Negative earnings and negative EBITDA keep traditional earnings-based valuation support limited.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Surmodics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →